Evidence map›Paper›PMID 42042815›Full record

ArticleVaccines2026

Antibody Responses After BA.5/BF.7 Breakthrough Infection in People Living with HIV.

Ying Liu, Zhaowei Guo, Zhuo Yang, Yaruo Qiu, Xinglin Li, Xin Li, Leidan Zhang, Danying Chen, Xuesen Zhao, Hongxin Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ying LiuClinical Center for HIV/AIDS, Beijing Ditan Hospital, Beijing 100015, China.
Zhaowei GuoBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Zhuo YangBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Yaruo QiuBeijing Key Laboratory of Tumor Systems Biology, Peking University Health Science Center, Beijing 100191, China.
Xinglin LiBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xin LiClinical Center for HIV/AIDS, Beijing Ditan Hospital, Beijing 100015, China.
Leidan ZhangClinical Center for HIV/AIDS, Beijing Ditan Hospital, Beijing 100015, China.
Danying ChenBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.
Xuesen ZhaoBeijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing 100015, China.ORCID 0000-0003-1286-5733
Hongxin ZhaoClinical Center for HIV/AIDS, Beijing Ditan Hospital, Beijing 100015, China.

Funding

Beijing Ditan Hospital Outstanding Young Talent Development Program ZZ202403Beijing Municipal Natural Science Foundation L222069National Key R&D Program of China 2023YFC2306000
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antibody-dependent cellular cytotoxicityantiretroviral therapybreakthrough infectionHIVimmune imprintingneutralizing antibodySARS-CoV-2

Identifiers

PMID42042815
PMCPMC13119647

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.